Dosage for Mavenclad
The cumulative dosage of 3.5 mg/kg Mavenclad is administered orally and divided into 2 treatment courses (1.75 mg/ kg per treatment course). Each treatment course is divided into 2 treatment cycles.
What Drugs, Substances, or Supplements Interact with Mavenclad?
Mavenclad may interact with immunosuppressive drugs, hematotoxic drugs, antiviral and antiretroviral drugs, ritonavir, eltrombopag, curcumin, cyclosporine, dilazep, nifedipine, nimodipine, cilostazol, sulindac, dipyridamole, reserpine, interferon-beta, corticosteroids, rifampicin, St. John’s wort, or hormonal contraceptives. Tell your doctor all medications and supplements you use.
Mavenclad During Pregnancy and Breastfeeding
Mavenclad is not recommended for use during pregnancy; it may harm a fetus. Pregnancy should be excluded before the initiation of each treatment course of Mavenclad. Females of reproductive potential should prevent pregnancy by use of effective contraception during Mavenclad dosing and for at least 6 months after the last dose in each treatment course. Males of reproductive potential should take precautions to prevent pregnancy of their partner during Mavenclad dosing and for at least 6 months after the last dose in each treatment course. Because of the potential for serious adverse reactions in nursing infants, Mavenclad is not recommended for use while breastfeeding.
Our Mavenclad (cladribine) Tablets, for Oral Use Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.